IGM Biosciences Inc (IGMS) — Financial Flexibility Index

Latest as of June 2025: -8.38x

IGM Biosciences Inc (IGMS) has a Financial Flexibility Index of -8.38x as of June 2025. Free cash flow of $-50.79 Million (operating CF $-50.79 Million minus capex $1.00K) represents -8% of total liabilities ($6.06 Million). Check IGMS total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.

Financial Flexibility Index

-8.38x
Free Cash Flow / Total Liabilities

Free Cash Flow

$-50.79 Million
Operating CF − Capex

Total Liabilities

$6.06 Million
USD

Capital Expenditures

$1.00K
USD

IGM Biosciences Inc Financial Flexibility Index (2017–2024)

Historical Financial Flexibility Index trend for IGM Biosciences Inc across 8 annual periods. For the full cash flow conversion analysis, see IGMS cash flow metrics.

Annual Financial Flexibility Index for IGM Biosciences Inc (2017–2024)

Year-by-year free cash flow to debt coverage for IGM Biosciences Inc. Explore IGM Biosciences Inc (IGMS) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.

Year Flexibility Index Free Cash Flow (USD) Operating CF Total Liabilities YoY Change
2024 -0.68x $-147.14 Million $-153.00 Million $217.54 Million ▲ +17.2%
2023 -0.82x $-179.85 Million $-192.23 Million $220.18 Million ▼ -4345.3%
2022 0.02x $4.35 Million $-5.85 Million $226.24 Million ▲ +100.9%
2021 -2.09x $-111.09 Million $-124.34 Million $53.22 Million ▼ -12.4%
2020 -1.86x $-49.80 Million $-67.30 Million $26.82 Million ▲ +8.3%
2019 -2.03x $-42.78 Million $-45.12 Million $21.12 Million ▼ -634.3%
2018 -0.28x $-19.26 Million $-20.04 Million $69.81 Million ▼ -15.9%
2017 -0.24x $-9.97 Million $-10.36 Million $41.89 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities